{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T18:56:21Z","timestamp":1767725781146,"version":"build-2238731810"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T00:00:00Z","timestamp":1749600000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Takeda (China) International Trading Co., Ltd."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s12325-025-03222-7","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T03:05:15Z","timestamp":1749611115000},"page":"5282-5299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Effect of Leuprolide Acetate 11.25 mg 3-Month Formulation in Children with Central Precocious Puberty: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"42","author":[{"given":"Linqi","family":"Han","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunjuan","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"La","family":"Da","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3057-8220","authenticated-orcid":false,"given":"Yan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,11]]},"reference":[{"key":"3222_CR1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/S2213-8587(15)00380-0","volume":"4","author":"AC Latronico","year":"2016","unstructured":"Latronico AC, Brito VN, Carel J-C. Causes, diagnosis, and treatment of central precocious puberty. Lancet Diabetes Endocrinol. 2016;4:265\u201374.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3222_CR2","doi-asserted-by":"publisher","first-page":"3073","DOI":"10.1007\/s00431-021-04022-1","volume":"180","author":"AV Cheuiche","year":"2021","unstructured":"Cheuiche AV, da Silveira LG, de Paula LCP, Lucena IRS, Silveiro SP. Diagnosis and management of precocious sexual maturation: an updated review. Eur J Pediatr. 2021;180:3073\u201387.","journal-title":"Eur J Pediatr"},{"key":"3222_CR3","doi-asserted-by":"publisher","first-page":"4305","DOI":"10.1210\/jc.2010-1025","volume":"95","author":"L Soriano-Guill\u00e9n","year":"2010","unstructured":"Soriano-Guill\u00e9n L, Corripio R, Labarta JI, Ca\u00f1ete R, Castro-Feij\u00f3o L, Espino R, et al. Central precocious puberty in children living in Spain: incidence, prevalence, and influence of adoption and immigration. J Clin Endocrinol Metab. 2010;95:4305\u201313.","journal-title":"J Clin Endocrinol Metab"},{"key":"3222_CR4","doi-asserted-by":"publisher","first-page":"e0141844","DOI":"10.1371\/journal.pone.0141844","volume":"10","author":"SH Kim","year":"2015","unstructured":"Kim SH, Huh K, Won S, Lee K-W, Park M-J. A significant increase in the incidence of central precocious puberty among Korean girls from 2004 to 2010. PLoS ONE. 2015;10:e0141844.","journal-title":"PLoS ONE"},{"key":"3222_CR5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/humupd\/7.3.292","volume":"7","author":"C-J Partsch","year":"2001","unstructured":"Partsch C-J. Pathogenesis and epidemiology of precocious puberty. Effects of exogenous oestrogens. Hum Reprod Upd. 2001;7:292\u2013302.","journal-title":"Hum Reprod Upd"},{"key":"3222_CR6","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/cen.14475","volume":"95","author":"L Maione","year":"2021","unstructured":"Maione L, Bouvattier C, Kaiser UB. Central precocious puberty: recent advances in understanding the aetiology and in the clinical approach. Clin Endocrinol. 2021;95:542\u201355.","journal-title":"Clin Endocrinol"},{"key":"3222_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/sexes2010010","volume":"2","author":"C Mucaria","year":"2021","unstructured":"Mucaria C, Tyutyusheva N, Baroncelli GI, Peroni D, Bertelloni S. Central precocious puberty in boys and girls: similarities and differences. Sexes. 2021;2:119\u201331.","journal-title":"Sexes"},{"key":"3222_CR8","doi-asserted-by":"publisher","first-page":"R18","DOI":"10.1186\/bcr3613","volume":"16","author":"DH Bodicoat","year":"2014","unstructured":"Bodicoat DH, Schoemaker MJ, Jones ME, McFadden E, Griffin J, Ashworth A, et al. Timing of pubertal stages and breast cancer risk: the Breakthrough Generations Study. Breast Cancer Res. 2014;16:R18.","journal-title":"Breast Cancer Res"},{"key":"3222_CR9","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S1470-2045(12)70425-4","volume":"13","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2012","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13:1141\u201351.","journal-title":"Lancet Oncol"},{"key":"3222_CR10","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1210\/jc.2011-2704","volume":"97","author":"PA Lee","year":"2012","unstructured":"Lee PA, Klein K, Mauras N, Neely EK, Bloch CA, Larsen L, et al. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metabol. 2012;97:1572\u201380.","journal-title":"J Clin Endocrinol Metabol"},{"key":"3222_CR11","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1210\/jcem-69-3-689","volume":"69","author":"KL Parker","year":"1989","unstructured":"Parker KL, Lee PA. Depot leuproltde acetate for treatment of precocious puberty. J Clin Endocrinol Metab. 1989;69:689\u201391.","journal-title":"J Clin Endocrinol Metab"},{"key":"3222_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2165\/00024677-200201050-00002","volume":"1","author":"JM Weiss","year":"2002","unstructured":"Weiss JM, Diedrich K, Ludwig M. Gonadotropin-releasing hormone antagonists: pharmacology and clinical use in women. Treat Endocrinol. 2002;1:281\u201391.","journal-title":"Treat Endocrinol"},{"key":"3222_CR13","doi-asserted-by":"publisher","unstructured":"Lahlou N, Carel J-C, Chaussain J-L, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonists: clinical implications in pediatrics. J Pediatr Endocrinol Metabol [Internet]. 2000. https:\/\/doi.org\/10.1515\/JPEM.2000.13.S1.723\/html.","DOI":"10.1515\/JPEM.2000.13.S1.723\/html"},{"key":"3222_CR14","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/j.1365-2265.2009.03584.x","volume":"71","author":"V Mericq","year":"2009","unstructured":"Mericq V, Lammoglia JJ, Unanue N, Villaroel C, Hern\u00e1ndez MI, \u00c1vila A, et al. Comparison of three doses of leuprolide acetate in the treatment of central precocious puberty: preliminary results. Clin Endocrinol. 2009;71:686\u201390.","journal-title":"Clin Endocrinol"},{"key":"3222_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/1043293","volume":"2022","author":"J Yang","year":"2022","unstructured":"Yang J, Song Q, Gao S, Gao Y, Shang X, Li G, et al. Efficacy of leuprorelin 3-month depot (11.25 mg) compared to 1-month depot (3.75 mg) for central precocious puberty in chinese girls: a prospective cohort study. Int J Endocrinol. 2022;2022:1\u20138.","journal-title":"Int J Endocrinol."},{"key":"3222_CR16","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1210\/jc.2001-020243","volume":"87","author":"J-C Carel","year":"2002","unstructured":"Carel J-C, Lahlou N, Jaramillo O, Montauban V, Teinturier C, Colle M, et al. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metabol. 2002;87:4111\u20136.","journal-title":"J Clin Endocrinol Metabol"},{"key":"3222_CR17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.6065\/apem.2040134.067","volume":"26","author":"MJ Jeon","year":"2021","unstructured":"Jeon MJ, Choe JW, Chung HR, Kim JH. Short-term efficacy of 1-month and 3-month gonadotropin-releasing hormone agonist depots in girls with central precocious puberty. Ann Pediatr Endocrinol Metab. 2021;26:171\u20137.","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"3222_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1687-9856-2011-7","volume":"2011","author":"PA Lee","year":"2011","unstructured":"Lee PA, Neely EK, Fuqua J, Yang D, Larsen LM, Mattia-Goldberg C, et al. Efficacy of leuprolide acetate 1-month depot for central precocious puberty (CPP): growth outcomes during a prospective, longitudinal study. Int J Pediatr Endocrinol. 2011;2011:7.","journal-title":"Int J Pediatr Endocrinol"},{"key":"3222_CR19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.6065\/apem.2013.18.4.173","volume":"18","author":"YJ Kim","year":"2013","unstructured":"Kim YJ, Lee HS, Lee YJ, Lim JS, Kim SY, Kim EY, et al. Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty. Ann Pediatr Endocrinol Metab. 2013;18:173.","journal-title":"Ann Pediatr Endocrinol Metab."},{"key":"3222_CR20","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.4103\/0366-6999.156773","volume":"128","author":"W-J Li","year":"2015","unstructured":"Li W-J, Gong C-X, Guo M-J, Xing J, Li T, Song W-H, et al. Efficacy and safety of domestic leuprorelin in girls with idiopathic central precocious puberty: a multicenter, randomized, parallel, controlled trial. Chin Med J. 2015;128:1314\u201320.","journal-title":"Chin Med J"},{"key":"3222_CR21","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1515\/jpem-2021-0142","volume":"34","author":"CO Ramos","year":"2021","unstructured":"Ramos CO, Canton APM, Seraphim CE, Faria AG, Tinano FR, Mendonca BB, et al. Anthropometric, metabolic, and reproductive outcomes of patients with central precocious puberty treated with leuprorelin acetate 3-month depot (11.25 mg). J Pediatr Endocrinol Metabol. 2021;34:1371\u20137.","journal-title":"J Pediatr Endocrinol Metabol."},{"key":"3222_CR22","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1210\/jc.2013-4471","volume":"99","author":"PA Lee","year":"2014","unstructured":"Lee PA, Klein K, Mauras N, Lev-Vaisler T, Bacher P. 36-Month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty. J Clin Endocrinol Metab. 2014;99:3153\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"3222_CR23","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.","DOI":"10.1371\/journal.pmed.1000097"},{"key":"3222_CR24","doi-asserted-by":"publisher","unstructured":"Appendix: Jadad Scale for Reporting Randomized Controlled Trials. Evid Based Obstetr Anesth [Internet]. 2005. https:\/\/doi.org\/10.1002\/9780470988343.app1.","DOI":"10.1002\/9780470988343.app1"},{"key":"3222_CR25","unstructured":"Ottawa Hospital Research Institute [Internet]. [cited 2024 Jul 2]. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"3222_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Mental Health. 2019;22:153\u201360.","journal-title":"Evid Based Mental Health"},{"key":"3222_CR27","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","volume":"45","author":"R DerSimonian","year":"2015","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015;45:139\u201345.","journal-title":"Contemp Clin Trials"},{"key":"3222_CR28","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JPT Higgins","year":"2003","unstructured":"Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"3222_CR29","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1471-2288-14-120","volume":"14","author":"JC Jakobsen","year":"2014","unstructured":"Jakobsen JC, Wetterslev J, Winkel P, Lange T, Gluud C. Thresholds for statistical and clinical significance in systematic reviews with meta-analytic methods. BMC Med Res Methodol. 2014;14:120.","journal-title":"BMC Med Res Methodol"},{"key":"3222_CR30","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1177\/21925682221110527","volume":"12","author":"JR Dettori","year":"2022","unstructured":"Dettori JR, Norvell DC, Chapman JR. Fixed-effect vs random-effects models for meta-analysis: 3 points to consider. Glob Spine J. 2022;12:1624\u20136.","journal-title":"Glob Spine J"},{"key":"3222_CR31","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1210\/jc.2005-1500","volume":"91","author":"A Badaru","year":"2006","unstructured":"Badaru A, Wilson DM, Bachrach LK, Fechner P, Gandrud LM, Durham E, et al. Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J Clin Endocrinol Metab. 2006;91:1862\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"3222_CR32","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jpeds.2011.05.036","volume":"159","author":"K Fuld","year":"2011","unstructured":"Fuld K, Chi C, Neely EK. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. J Pediatr. 2011;159:982-987.e1.","journal-title":"J Pediatr"},{"key":"3222_CR33","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1515\/jpem-2017-0523","volume":"31","author":"KO Klein","year":"2018","unstructured":"Klein KO, Dragnic S, Soliman AM, Bacher P. Predictors of bone maturation, growth rate and adult height in children with central precocious puberty treated with depot leuprolide acetate. J Pediatr Endocrinol Metab. 2018;31:655\u201363.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"3222_CR34","doi-asserted-by":"crossref","unstructured":"Mericq G MV, Youlton R R, Willshaw Z ME. Efectividad de la terapia con leuprolide acetato de dep\u00f3sito cada tres meses en pubertad precoz central. Rev m\u00e9d Chile [Internet]. 2006 [cited 2023 Jan 30];134. http:\/\/www.scielo.cl\/scielo.php?script=sci_arttext&pid=S0034-98872006000700003&lng=en&nrm=iso&tlng=en","DOI":"10.4067\/S0034-98872006000700003"},{"key":"3222_CR35","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1080\/09513590.2020.1770723","volume":"36","author":"A Vatopoulou","year":"2020","unstructured":"Vatopoulou A, Roos E, Daniilidis A, Dinas K. Long-term effects of treatment of central precocious puberty with gonadotropin-releasing hormone analogs every three months. Gynecol Endocrinol. 2020;36:1124\u20136.","journal-title":"Gynecol Endocrinol"},{"key":"3222_CR36","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1515\/jpem-2023-0410","volume":"37","author":"S Huang","year":"2024","unstructured":"Huang S, Zhang L, Gao C, Ou H, Hou L, Liu Z, et al. Efficacy and safety of leuprorelin 3-month depot (11.25 mg) for idiopathic central precocious puberty treatment of Chinese girls: a single-center retrospective study. J Pediatr Endocrinol Metabol. 2024;37:15\u201320.","journal-title":"J Pediatr Endocrinol Metabol."},{"key":"3222_CR37","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000456545","volume":"87","author":"A Durand","year":"2017","unstructured":"Durand A, Tauber M, Patel B, Dutailly P. Meta-analysis of paediatric patients with central precocious puberty treated with intramuscular triptorelin 11.25 mg 3-month prolonged-release formulation. Horm Res Paediatr. 2017;87:224\u201332.","journal-title":"Horm Res Paediatr"},{"key":"3222_CR38","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2021.36.e219","volume":"36","author":"LY Chung","year":"2021","unstructured":"Chung LY, Kang E, Nam H-K, Rhie Y-J, Lee K-H. Efficacy of triptorelin 3-month depot compared to 1-month depot for the treatment of Korean girls with central precocious puberty in single tertiary center. J Korean Med Sci. 2021;36: e219.","journal-title":"J Korean Med Sci"},{"key":"3222_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1100\/2012\/583751","volume":"2012","author":"E Chiocca","year":"2012","unstructured":"Chiocca E, Dati E, Baroncelli GI, Cassio A, Wasniewska M, Galluzzi F, et al. Central precocious puberty: treatment with triptorelin 11.25 mg. Sci World J. 2012;2012:1\u20136.","journal-title":"Sci World J"},{"key":"3222_CR40","doi-asserted-by":"publisher","unstructured":"Mart\u00ednez-Aguayo A, Hern\u00e1ndez MI, Beas F, I\u00f1iguez G, \u00c1vila A, Sovino \u0397, et al. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation. J Pediatr Endocrinol Metabol [Internet]. 2006. https:\/\/doi.org\/10.1515\/JPEM.2006.19.8.963\/html","DOI":"10.1515\/JPEM.2006.19.8.963\/html"},{"key":"3222_CR41","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000028158","volume":"100","author":"X Luo","year":"2021","unstructured":"Luo X, Hou L, Zhong Y, You C, Yang Y, Wu X, et al. An open label, multicenter clinical trial that investigated the efficacy and safety of leuprorelin treatment of central precocious puberty in Chinese children. Medicine. 2021;100: e28158.","journal-title":"Medicine"},{"key":"3222_CR42","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000501336","volume":"91","author":"K Bangalore Krishna","year":"2019","unstructured":"Bangalore Krishna K, Fuqua JS, Rogol AD, Klein KO, Popovic J, Houk CP, et al. Use of gonadotropin-releasing hormone analogs in children: update by an International Consortium. Horm Res Paediatr. 2019;91:357\u201372.","journal-title":"Horm Res Paediatr"},{"key":"3222_CR43","doi-asserted-by":"crossref","unstructured":"Carel J-C, Eugster EA, Rogol A, Ghizzoni L, Palmert MR, on behalf of the members of the ESPE-LWPES GnRH Analogs Consensus Conference Group. Consensus statement on the use of gonadotropin-releasing hormone analogs in Children. Pediatrics. 2009;123:e752\u201362.","DOI":"10.1542\/peds.2008-1783"}],"updated-by":[{"DOI":"10.1007\/s12325-025-03315-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03222-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03222-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03222-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T21:02:33Z","timestamp":1762030953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03222-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,11]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["3222"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03222-7","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,11]]},"assertion":[{"value":"17 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-025-03315-3","URL":"https:\/\/doi.org\/10.1007\/s12325-025-03315-3","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors Linqi Han, Chunjuan Zhai and Yan Sun have received research funding from Takeda (China) International Trading Co., Ltd. La Da is an employee of Takeda (China) International Trading Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}